RGNX · Healthcare · $414M
After-hours $8.00+6.24%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
3/'26
12/'25 vs prev quarter
Among 327 Biotechnology peers
Quarterly Revenue Growth
“RGX-202 피벗 임상 3상이 1차 목표를 높은 통계적 유의성으로 달성했어요 — 환자 93%에서 미세디스트로핀 발현이 기준치(10%)를 넘었고”
In the company's words · 2026 1분기 earnings call